Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Keio Upstart, Novo Nordisk Ink Global Deal on iPSC-Based Heart Therapy
June 2, 2021
- Amgen Gets Rights to Kyowa Kirin’s Atopic Dermatitis Drug
June 2, 2021
- Incyte’s Debuts Its 1st Product in Japan; Mitsubishi’s Uplizna Now Available Too
June 2, 2021
- FDA Target Date for Vadadustat Set for March 29: Otsuka/Akebia
June 2, 2021
- Shionogi, Chiyoda Eye JV for Continuous Manufacturing of APIs, Intermediates
June 2, 2021
- SGLT2 Inhibitors Again Poised for Double-Digit Growth in FY2021; Forxiga Overtakes Jardiance in April
June 1, 2021
- 52 More Nichi-Iko Products Face Supply Stoppage as Risk Assessment Continues
June 1, 2021
- Jail Terms Sought for 2 Ono Employees over Onoact-Tied Bribery Charges
June 1, 2021
- Chugai Becomes 1st Japan Drug Maker to Introduce Cryo-EM
June 1, 2021
- AstraZeneca Seeks Japan Approval for Tezepelumab in Severe Asthma
June 1, 2021
- Nipro Rolls Out Seven-Dose Syringe for Pfizer COVID-19 Vaccine
June 1, 2021
- Sanofi Introduces 1st NovoRapid Biosimilar in Japan
June 1, 2021
- Ayumi Curbs Enbrel Biosimilar Shipments in Fallout from Indian API Supply Disruption
June 1, 2021
- Pfizer Vaccine Now OK’ed for Adolescents, 1-Month Storage in Refrigerators
June 1, 2021
- Kobayashi Kako Submits Biz Improvement Plan Over Fudged Drug Filings
May 31, 2021
- EA Pharma/Kissei Seek Japan Approval of Ulcerative Colitis Drug
May 31, 2021
- AZ to Take Over Japan Synagis Rights from AbbVie in July as Global Pact Expires
May 31, 2021
- Yoshindo/Teijin Halt Enbrel Shipments as COVID-19 Stalls Indian API Supplies
May 31, 2021
- mRNA CDMO Arcalis Aims for One Stop Provider for Seed Verification, R&D, Commercial Production
May 31, 2021
- US Approves Myovant’s Relugolix Combo for Uterine Fibroids
May 28, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…